Lightlake Therapeutics Inc. To Present At The Third Annual Marcum MicroCap Conference - WNEM TV 5

Lightlake Therapeutics Inc. To Present At The Third Annual Marcum MicroCap Conference

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Lightlake Therapeutics Inc.

LONDON, May 22, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel.

Lightlake's presentation by CEO Dr. Roger Crystal is scheduled to begin at 4:30 p.m. EDT and he will be available for one-on-one meetings during the conference.

The annual Marcum MicroCap Conference is a signature showcase for superior quality, under-followed public companies with less than $500 million in market capitalization.

For more information or to register, please visit the conference website at http://www.marcumllp.com/microcap or download the free official conference app for the iPhone, iPad, or for Android mobile devices in Apple's App Store and the Google Play Market.

About Lightlake Therapeutics Inc.

Lightlake Therapeutics Inc., a biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative intranasal naloxone solutions to common addictions and related disorders. Lightlake is developing a treatment to reverse opioid overdoses, which have reached epidemic proportions in the United States. Lightlake has successfully completed a clinical trial for this treatment in collaboration with the National Institute on Drug Abuse, part of the National Institutes of Health. Lightlake also has successfully completed a Phase II clinical trial to treat Binge Eating Disorder. For more information please visit: http://www.lightlaketherapeutics.com.

About Marcum LLP

Marcum LLP is one of the largest independent public accounting and advisory services firms in the United States. Ranked #15 nationally, Marcum LLP offers the resources of 1,300 professionals, including over 160 partners, in 23 offices throughout the U.S., Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep, with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting. The Marcum Group companies include Marcum LLP; Marcum Technology LLC; Marcum Search LLC; Marcum Financial Services LLC; Marcum Bernstein & Pinchuk LLP; MarcumBuchanan Associates LLC; and Marcum Cronus Partners LLC. For more information, visit www.marcumllp.com.

Corporate Contact:
Lightlake Therapeutics Inc.
Dr. Roger Crystal, CEO
+44(0)203 617 8739
info@lightlaketherapeutics.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
WNEM
Powered by WorldNow CNN
All content © 2014, WNEM; Saginaw, MI. (A Meredith Corporation Station) and WorldNow. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.